• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Bio-Path Holdings Inc.

    10/22/24 3:11:40 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPTH alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001133818
    BIO-PATH HOLDINGS INC
    OGDEN GOLF CO CORP
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    BIO-PATH HOLDINGS, INC.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    BIO-PATH HOLDINGS, INC.
    Street Address 1 Street Address 2
    4710 BELLAIRE BOULEVARD SUITE 210
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    BELLAIRE TEXAS 77401 (832) 742-1357

    3. Related Persons

    Last Name First Name Middle Name
    Nielsen Peter H.
    Street Address 1 Street Address 2
    4710 Bellaire Boulevard Suite 210
    City State/Province/Country ZIP/PostalCode
    Bellaire TEXAS 77401
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cleaver Heath W.
    Street Address 1 Street Address 2
    4710 Bellaire Boulevard Suite 210
    City State/Province/Country ZIP/PostalCode
    Bellaire TEXAS 77401
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Aubert Paul D.
    Street Address 1 Street Address 2
    4710 Bellaire Boulevard Suite 210
    City State/Province/Country ZIP/PostalCode
    Bellaire TEXAS 77401
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Morris Douglas P,
    Street Address 1 Street Address 2
    4710 Bellaire Boulevard Suite 210
    City State/Province/Country ZIP/PostalCode
    Bellaire TEXAS 77401
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sherwood Aline
    Street Address 1 Street Address 2
    4710 Bellaire Boulevard Suite 210
    City State/Province/Country ZIP/PostalCode
    Bellaire TEXAS 77401
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-10-08    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    H.C. Wainwright & Co., LLC 375
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    430 Park Avenue
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10022
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
    X All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $3,995,403 USD
    or    Indefinite
    Total Amount Sold $3,995,403 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    Includes the gross proceeds received in the offering.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $340,000 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    H.C. Wainwright & Co., LLC received the above sales commission and warrants to purchase up to an aggregate of 344,828 shares of the Company's common stock, par value $0.001 per share at an exercise price equal to $1.0875 per share as compensation.

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    BIO-PATH HOLDINGS, INC. /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer 2024-10-22

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $BPTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BPTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BPTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sherwood Aline

    4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

    8/1/24 6:14:31 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Aubert Paul

    4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

    8/1/24 6:10:56 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Cleaver Heath

    4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

    8/1/24 6:07:55 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Investor Forum: Now Available for Online Viewing

    NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad

    6/13/25 8:35:00 AM ET
    $ATNM
    $BPTH
    $COCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Nursing Services

    Life Sciences Investor Forum Agenda Announced for June 11th-12th

    NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co

    6/10/25 2:38:09 PM ET
    $ATNM
    $BPTH
    $COCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Nursing Services

    Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

    HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced Peter Nielsen, Chief Executive Officer, will present a corporate overview at the Life Sciences Virtual Investor Forum on Thursday, June 12 at 12:00 p.m. ET. A live stream of the presentation will be available here and on the Investor Relations section of Bio-Path's website, where it will be archived for approximately 90 days. About Bio-Path Holdings, Inc. Bio-Path is a biotechnology company developing DNAbilize®, a

    6/9/25 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    SEC Filings

    View All

    SEC Form 10-Q filed by Bio-Path Holdings Inc.

    10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    1/13/26 11:47:25 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by Bio-Path Holdings Inc.

    NT 10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    11/17/25 3:07:55 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings Inc. filed SEC Form 8-K: Leadership Update, Other Events

    8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    11/14/25 12:10:42 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Bio-Path

    Roth Capital initiated coverage of Bio-Path with a rating of Buy

    3/11/21 7:29:52 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH Capital initiated coverage on Bio-Path with a new price target

    ROTH Capital initiated coverage of Bio-Path with a rating of Buy and set a new price target of $13.00

    3/11/21 7:25:18 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

    SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

    11/13/24 11:15:11 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

    SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

    11/6/24 4:52:04 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Bio-Path Holdings Inc.

    SC 13G - BIO-PATH HOLDINGS INC (0001133818) (Subject)

    4/3/24 5:44:32 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Leadership Updates

    Live Leadership Updates

    View All

    Bio-Path Holdings Appoints Aline Sherwood to Board of Directors

    HOUSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Aline Sherwood to its Board of Directors on March 31, 2022. Ms. Sherwood replaced Martina Molsbergen, who stepped down from the Board of Directors on February 14, 2022. "We are delighted to welcome Aline to the Bio-Path Board of Directors. With her extensive background in biotechnology communications, Aline synthesizes complex science into compelling messaging, which is instrumental in guiding our communications

    4/6/22 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    Financials

    Live finance-specific insights

    View All

    Bio-Path Holdings Provides Clinical and Operational Update

    HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An archived webcast of the event can be accessed here. "Our business model centers around generating new drug candidates from our DNAbilize® platform and licensing them for final development and commercialization with partners that have expertise and scale to successfully bring them to market," sa

    6/3/25 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

    HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, www.biopathho

    5/22/25 4:30:00 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings Reports Full Year 2024 Financial Results

    HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December 31, 2024 and provided an update on recent corporate developments. "We are merely touching the tip of the iceberg in terms of realizing the potential of our DNAbilize® platform to change the treatment paradigm in both obesity and oncology," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. "Throughout the last year, we built on the bo

    3/28/25 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care